Description

Simple

A medication applied to the eyes to help prepare for eye surgery and also used to lower pressure in the eye.

Clinical

A direct acting miotic agent administered ophthalmically to decrease intraocular pressure in glaucoma or after eye surgery, and to induce miosis during surgery.

Overview

A slowly hydrolyzed cholinergic agonist that acts at both muscarinic and nicotinic receptors.

Pharmacology

Indication

Primarily used in the treatment of glaucoma, but is also used during ophthalmic surgery.

Pharmacodynamic

Carbachol is a potent cholinergic (parasympathomimetic) agent which produces constriction of the iris and ciliary body resulting in reduction in intraocular pressure. The exact mechanism by which carbachol lowers intraocular pressure is not precisely known. In the cat and rat, carbachol is well-know... Read more

Mechanism of action

Carbachol is a parasympathomimetic that stimulates both muscarinic and nicotinic receptors. In topical ocular and intraocular administration its principal effects are miosis and increased aqueous humour outflow.

Absorption

Carbachol displays limited absorption from the gastrointestinal tract and it is not reported to cross the blood-brain barrier.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Oral, mouse: LD50 = 15 mg/kg; Oral, rat: LD50 = 40 mg/kg.

Adverse Effects

Contraindications

  • Route:
    • Intraocular
  • Dose Form:
    • Injection
  • Hypersensitivity:
    • true
  • Regions: US

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Carbamoylcholine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1,10-Phenanthroline
The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Carbamoylcholine.
Acebutolol
The risk or severity of adverse effects can be increased when Acebutolol is combined with Carbamoylcholine.
Acotiamide
The risk or severity of adverse effects can be increased when Acotiamide is combined with Carbamoylcholine.
Alprenolol
The risk or severity of adverse effects can be increased when Alprenolol is combined with Carbamoylcholine.
Ambenonium
The risk or severity of adverse effects can be increased when Ambenonium is combined with Carbamoylcholine.
Amikacin
The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Amikacin.
Anisodamine
The risk or severity of adverse effects can be increased when Anisodamine is combined with Carbamoylcholine.
Apramycin
The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Apramycin.
Aprotinin
The risk or severity of adverse effects can be increased when Aprotinin is combined with Carbamoylcholine.
Arbekacin
The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Arbekacin.
Arotinolol
The risk or severity of adverse effects can be increased when Arotinolol is combined with Carbamoylcholine.
Atenolol
The risk or severity of adverse effects can be increased when Atenolol is combined with Carbamoylcholine.
Bambuterol
The risk or severity of adverse effects can be increased when Bambuterol is combined with Carbamoylcholine.
Befunolol
The risk or severity of adverse effects can be increased when Befunolol is combined with Carbamoylcholine.
Bekanamycin
The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Bekanamycin.
Betaxolol
The risk or severity of adverse effects can be increased when Betaxolol is combined with Carbamoylcholine.
Bevantolol
The risk or severity of adverse effects can be increased when Bevantolol is combined with Carbamoylcholine.
Bisoprolol
The risk or severity of adverse effects can be increased when Bisoprolol is combined with Carbamoylcholine.
Bopindolol
The risk or severity of adverse effects can be increased when Bopindolol is combined with Carbamoylcholine.
Bucindolol
The risk or severity of adverse effects can be increased when Bucindolol is combined with Carbamoylcholine.